Data support the therapeutic potential of Amylin's integrated neurohormonal approach to obesity pharmacotherapy

SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that new data for its pipeline obesity candidates will be presented at the 2008 Annual Scientific Meeting of The Obesity Society in Phoenix October 3-7. The Obesity Society's annual meeting is one of the largest and most comprehensive scientific conferences in the field of obesity.

Amylin will present scientific data through 11 oral and poster presentations, showcasing progress in the company's obesity pipeline. In addition to Amylin's lead clinical-stage programs in obesity, pramlintide/metreleptin and AC2307, new findings will also be presented on various preclinical programs, including a new Y-family mimetic and Amylin's peptide hybrid (phybrid) platform. Additional information will be presented during two corporate-sponsored symposia focused on the emerging peptide hormone approach to the treatment of obesity and the new science and therapeutic research that shows promise to reduce the risk of cardiovascular disease associated with obesity and type 2 diabetes.

'We are excited to present our latest work on the obesity front at this year's Obesity Society meeting, and will be sharing compelling data that demonstrates how our programs have the potential to provide significant weight loss that can be sustained over time,' said Daniel Bradbury, president and chief executive officer at Amylin Pharmaceuticals, Inc. 'Our unique neurohormonal approach to obesity, and our deep expertise in peptide hormones, enables us to develop drugs that may help regulate how many calories we eat, burn and store as fat by mimicking the effects of naturally occurring hormones. Amylin's approach has the potential to achieve significant weight loss with a reduced risk for side effects that are often seen with other obesity treatments.'

    KEY AMYLIN ACTIVITIES AT THE OBESITY SOCIETY MEETING
    1.  Invited symposium presentation: 'Therapeutic Potential of Leptin in
        General Obesity: A New, Integrated Neurohormonal Approach' will be
        presented by Christian Weyer, MD, Vice President, Corporate
        Development for Diabetes and Obesity at Amylin Pharmaceuticals, Inc.,
        as part of a symposium entitled 'Leptin: From Bench to Bedside' on
        Sunday, October 5 from 3:45-5:30 p.m. PT (6:45 p.m. ET). This
        symposium is part of the conference's core scientific program.
    2.  Oral 64-OR: 'Enhanced weight loss following pramlintide/metreleptin
        combination treatment in overweight and obese subjects is accompanied
        by improved control of eating' will be presented by Steve Smith, MD,
        Sunday, October 5 at 11:45 a.m. PT (2:45 p.m. ET).
    3.  Poster 323-P: 'Safety of 360 ug pramlintide BID treatment for up to 2
        years' will be presented by Nicole Kesty, PhD, Saturday, October 4 at
        5 p.m. PT (8 p.m. ET).
    4.  Poster 592-P: 'Changes in weight and binge eating scale scores in
        obese subjects treated with pramlintide as monotherapy and in
        combination with oral weight loss agents' will be presented by Fulton
        Velez, MD, Sunday, October 5 at 5:30 p.m. PT (8:30 p.m. ET).
    5.  Poster 205-P: 'Effects of amylin/leptin lead-in on the weight-reducing
        effects of amylin and/or leptin in diet-induced obese (DIO) rats' will
        be presented by Chunli Lei, Saturday, October 4 at 5 p.m. PT
        (8 p.m. ET).
    6.  Poster 651-P: 'AC2307, an amylin mimetic, reduced 24-h food intake in
        obese subjects without changing subjective perceptions of hunger and
        fullness' will be presented by Nico Pannacciulli, MD, PhD, Sunday,
        October 5 at 5:30 p.m. PT (8:30 p.m. ET).
    7.